UK biotech venture investment reaches five-year high in Q2 2026, driven by record private financing

• UK biotech venture investment reaches a five-year high, with £2.05 billion raised in Q2 2026.
• UK cements its position as Europe’s biotech investment leader, attracting over 60% of European VC.
• Isomorphic Labs’ £1.6 billion Series B drives a landmark quarter for UK AI-led drug discovery.
• Private capital rebounds strongly, but public markets continue to lag with no UK biotech IPOs in 2026.

London, 20 July 2026 – UK biotech financing hit a five-year high in the second quarter of 2026, with total equity financing reaching £2.11 billion, including a record £2.05 billion in venture capital, according to new figures from the BioIndustry Association (BIA).

A landmark quarter for UK biotech venture investment

The quarter was dominated by Isomorphic Labs’ landmark £1.6 billion Series B round, a major validation of the UK’s global leadership in AI-driven drug discovery. Even excluding this record financing, UK biotech companies secured £498 million in venture capital during Q2 – almost double the £279 million raised in Q2 2025.

Building on the positive momentum seen in Q1, Q2 2026 has delivered the strongest quarter for UK biotech venture investment in the past five years. The UK also strengthened its position as Europe’s leading biotech investment destination, accounting for 61% of Europe’s £3.3 billion venture capital total during the quarter.

Beyond the headline megadeal, the funding landscape became increasingly balanced. Seed investment remained resilient, with eight seed deals completed during the quarter and rounds averaging £6.4 million as companies bypassed smaller historic structures to raise substantial first financings. Series A- and B+-stage companies each raised £190 million and £225 million respectively, and the critical £10 million–£25 million funding bracket has seen a welcome uptick. Twice as many companies in the latter tier raised rounds in the first half of 2026 compared to the total recorded during the whole of 2025.

Public markets continue to lag private capital

While UK public markets showed modest signs of improvement, they continued to trail the strength of private financing. Follow-on financing reached £58 million in Q2 2026, a 61% increase from £36 million in Q1 and significantly above the £15 million raised in Q2 2025. However, no UK biotech IPOs have occurred thus far in 2026 and there was no follow-on activity by UK biotech companies listed on NASDAQ.

Institutional momentum builds behind UK scale-ups

The report points to growing institutional support for the sector. Nest’s landmark £1 billion venture capital push for UK pension savers via the Schroders Capital UK Innovation LTAF will channel domestic capital into high-growth scale-ups. The British Business Bank has also deployed capital at increased pace to venture funds. Its £25 million investment into Alchemab – its largest direct life sciences investment to date – is a similarly positive indicator for the sector. Alongside Novartis’ $1.5 billion acquisition of Myricx Bio, these developments show a recovery in UK biotech financing supported by private investment and world-class valuations for UK science with important recyclable returns that can be reinvested into the next generation of companies.

Chris Molloy, CEO of BIA, said:

This quarter shows continued improvement in funding confidence and deal flow right across the UK biotech sector. Its major headline is the strongest single quarter for UK life sciences venture funding in the last five years with over £2 billion in venture capital placed. It has seen fundraising rounds from Seed to Series D at world class valuations.

Our collective focus must be to ensure that this momentum is maintained and that the proven returns our investors are making attract more institutional investors to back this sector with growth capital. UK public markets need to recognise, cover and return to backing our sector and private momentum must be joined by robust, public sector-managed, investor-advised translational funding. This combination will de-risk the early-to-mid stage companies and sustain growth across every tier of the sector, making the whole of the UK fit to fund.

ENDS

About the BioIndustry Association (BIA):

The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation.

BIA has over 600 members spanning human health and non-health biotech, including start-ups, scale-ups and established global companies. Membership also encompasses the full UK ecosystem, including non-commercial research institutions and service providers. BioIndustry Association | BIA